Immutep

Business Opportunities



    Business Relations Contact

    John B. Hawken
    President and CEO
    jbhawken@immutep.com

    Parc Club Orsay
    2, rue Jean Rostand
    91893 Orsay cedex, France
    Telephone:+33 1 69289992
    Fax: +33 1 69078221

» Investor Relations
© 2002 Immutep, S.A.
Press Release
10/2008 - IMP321 IND Allowance in Pancreatic Cancer
image Immutep S.A. announced today that the FDA, after review of the ...
06/2008 - LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy
image Immutep S.A. announced today the publication of research conducted by ...
11/2007 - IMP321 first results in metastatic breast cancer
image Immutep S.A announced positive interim results from a Phase I/II ...
09/2007 - IMP321’s potency as a new immunopotentiator in cancer patients
image Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide ...
09/2007 - Entering Phase I
image lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I ...